Follow
Tumor Markers
Tumor Marker: a biomarker found in the body system that can be elevated by the presence of all types of cancer. Each tumor marker is indicative of a particular disease process, and are used in oncology to help detect the presence of cancer.
SEP 15, 2020 | 8:00 AM
DATE: September 15, 2020 TIME: 08:00am PT Tumorigenesis and cancer progression are affected by the tumor immune microenvironment (TIME). The TIME not only influences the efficiency of existi...
JUN 30, 2020 | 9:00 AM
DATE: June 30, 2020 TIME: 9:00am PDT, 12:00pm EDT QC laboratories perform a critical role in demonstrating pharmaceutical products are consistently manufactured, safe, potent, and pure. At t...
JUN 30, 2020 | 8:00 AM
DATE: June 30, 2020 TIME: 8:00am PT, 11:00am Understanding the tumor microenvironment (TME) is essential for the development of effective treatments for cancer patients. Traditional multi...
JUN 17, 2020 | 1:30 PM
Understanding the complex interplay between a pathogen and the host response is important to developing effective vaccines and therapeutics. The nCounter® Analysis System and GeoMx®...
JUN 03, 2020 | 4:00 PM
The RNAscope in situ hybridization technology allows high sensitivity, specificity and spatial resolution providing pivotal single-cell gene expression information to gain better insights in...
JUN 03, 2020 | 12:00 PM
A key step in the clinical production of CAR T cells is the expansion of engineered T cells. To generate enough cells for viable adoptive cell therapy, cells must be robustly stimulated, whi...
JUN 03, 2020 | 9:30 AM
Cancer cells can acquire immune resistance resulting in a loss of immunosurveillance. Tumor cells can upregulate PDL-1 which binds to PD-1. This complex inhibits CD8 Tumor Infiltrating cells...
JUN 03, 2020 | 6:00 AM
Immune checkpoint therapies targeting the CTLA-4 and PD-(L)1 pathways have been largely clinically disappointing for patients with prostate cancer. This can be attributed to the highly immun...
JUN 03, 2020 | 12:00 AM
Programmed death-1 (PD-1) inhibits T and B cell function upon ligand binding. PD-1 blockade revolutionized cancer treatment, and while numerous patients respond, some develop autoimmune-like...
MAY 20, 2020 | 1:15 PM
Background: Acute myeloid leukemia (AML) is a molecularly and clinically heterogeneous hematological malignancy. Despite recent advancements in the treatment of AML, approximately 50% of pat...
